1-6 of 6
Boris Shor
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract LB042: A potent FGFR4-targeted antibody-drug conjugate therapy for patients with rhabdomyosarcoma and other cancers expressing FGFR4

Meijie Tian, Katrina Jia, Jerry T. Wu, Jun S. Wei, Adam T. Cheuk, Zhongmei Zhang, Eleanor G. Pope, Boris Shor, L. Nathan Tumey, Javed Khan
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): LB042.
https://doi.org/10.1158/1538-7445.AM2024-LB042
Published: 05 April 2024
View article titled, Abstract LB042: A potent FGFR4-targeted antibody-drug conjugate therapy for patients with rhabdomyosarcoma and other cancers expressing FGFR4
Journal Articles

Abstract 2463: Enhanced anti-tumor activity of an Auristatin-based antibody-drug conjugate in combination with PI3K/mTOR inhibitors or taxanes: Translational implications and mechanistic insights

Puja Sapra, Boris Shor, Maureen Dougher, Jennifer Kahler, Michelle Mack, Jane Xu, Shuyan Lu, Eugene Melamud, Fang Wang, Edward Rosfjord
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 2463.
https://doi.org/10.1158/1538-7445.AM2015-2463
Published: 01 August 2015
View article titled, Abstract 2463: Enhanced anti-tumor activity of an Auristatin-based antibody-drug conjugate in combination with PI3K/mTOR inhibitors or taxanes: Translational implications and mechanistic insights
Journal Articles

Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2

Ker Yu, Celine Shi, Lourdes Toral-Barza, Judy Lucas, Boris Shor, Jae Eun Kim, Wei-Guo Zhang, Robert Mahoney, Christine Gaydos, LuAnna Tardio, Sung Kyoo Kim, Roger Conant, Kevin Curran, Joshua Kaplan, Jeroen Verheijen, Semiramis Ayral-Kaloustian, Tarek S. Mansour, Robert T. Abraham, Arie Zask, James J. Gibbons
Journal: Cancer Research
Cancer Res (2010) 70 (2): 621–631.
https://doi.org/10.1158/0008-5472.CAN-09-2340
Published: 13 January 2010
View article titled, Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2
Open the PDF for Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2 in another window
Includes: Supplementary data
Journal Articles

Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

Ker Yu, Lourdes Toral-Barza, Celine Shi, Wei-Guo Zhang, Judy Lucas, Boris Shor, Jamie Kim, Jeroen Verheijen, Kevin Curran, David J. Malwitz, Derek C. Cole, John Ellingboe, Semiramis Ayral-Kaloustian, Tarek S. Mansour, James J. Gibbons, Robert T. Abraham, Pawel Nowak, Arie Zask
Journal: Cancer Research
Cancer Res (2009) 69 (15): 6232–6240.
https://doi.org/10.1158/0008-5472.CAN-09-0299
Published: 29 July 2009
View article titled, Biochemical, Cellular, and <em>In vivo</em> Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin
Open the PDF for Biochemical, Cellular, and <em>In vivo</em> Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin in another window
Includes: Supplementary data
Journal Articles

Abstract #3713: Preclinical pharmacology and antitumor activity of a new class of ATP-competitive and highly selective inhibitors of the mammalian target of rapamycin (mTOR)

Ker Yu, Lourdes Toral-Barza, Celine Shi, Wei-Guo Zhang, Judy Lucas, Michael Cinque, Jamie Kim, Boris Shor, Jeroen verheijen, Kevin Curran, Joshua Kaplan, David Richard, Pawel Nowak, Derek Cole, Inder Chaudhary, John Ellingboe, Semiramis Ayral-Kaloustian, Tarek Mansour, James Gibbons, Robert Abraham, Arie Zask
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 3713.
Published: 01 May 2009
View article titled, Abstract #3713: Preclinical pharmacology and antitumor activity of a new class of ATP-competitive and highly selective inhibitors of the mammalian target of rapamycin (mTOR)
Journal Articles

A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis

Boris Shor, Wei-Guo Zhang, Lourdes Toral-Barza, Jessica Lucas, Robert T. Abraham, James J. Gibbons, Ker Yu
Journal: Cancer Research
Cancer Res (2008) 68 (8): 2934–2943.
https://doi.org/10.1158/0008-5472.CAN-07-6487
Published: 15 April 2008
View article titled, A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis
Open the PDF for A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis in another window
Includes: Supplementary data